CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 83 enrolled
Drug / intervention
Lithium Carbonate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03185208
NCT03185208Phase 4Completed

Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia

Ariel Gildengers, MD·interventional·Posted Jun 14, 2017·Updated Sep 11, 2025

In Brief

A Phase 4 clinical trial evaluating Lithium Carbonate and Placebo oral capsule for Mild Cognitive Impairment. Completed, enrolled 83 participants across 1 site.

Detailed Summary

Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure. Many studies suggest that lithium treatment may delay dementia onset or slow its progression. However, more research is needed to understand the extent of its anti-dementia properties if it will be deployed broadly in the general population. This study will examine whether lithium has anti-dementia properties in older adults who have mild cognitive impairment and are at risk of becoming demented.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJun 14, 2017
Enrollment StartFeb 2, 2018
Primary CompletionAug 6, 2024
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 9.0 years ago

Interventions

Lithium Carbonatedrug

See lithium carbonate arm

Placebo oral capsuledrug

See placebo arm